AI Article Synopsis

  • * A study analyzed adverse event reports from the FDA (2014-2019) to compare AF incidents between SGLT2i and other glucose-lowering medications, finding that AF was reported less frequently with SGLT2i (4.8 per 1000) than with other drugs (8.7 per 1000).
  • * The results indicate a consistent protective effect of SGLT2i against AF, reinforcing evidence from clinical trials regarding their benefits.

Article Abstract

Background: Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS).

Methods: We mined the FAERS from 2014q1 to 2019q4 to compare AF reporting for SGLT-2 i versus reports for other glucose lowering medications (ATC10 class). Several exclusions were sequentially applied for: concomitant medications; diabetes, cardiovascular or renal disease indication; reports for competing adverse events (genitourinary tract infections, ketoacidosis, Fournier's gangrene, amputation). We provide descriptive statistics and calculated proportional reporting ratios (PRR).

Results: There were 62,098 adverse event reports for SGLT2i and 642,031 reports for other ATC10 drugs. The reporting of AF was significantly lower with SGLT2i than with other ATC10 drugs (4.8 versus 8.7/1000; p < 0.001) with a PRR of 0.55 (0.49-0.62). Results did not change substantially after excluding reports listing insulin (PRR 0.49) or anti-arrhythmics (PRR 0.59) as suspect or concomitant drugs, excluding reports with indications for cardiovascular disease (PRR 0.49) or renal disease (PRR 0.55), and those filed for competing adverse events (PRR 0.63). Results were always statistically significant whether the diabetes indication was specified. Negative and positive controls confirmed internal validity of the database.

Conclusions: In a large pharmacovigilance database, AF was robustly and consistently reported more frequently for diabetes medications other than SGLT2i. This finding complements available evidence from trials supporting a protective role of SGLT2i against the occurrence of AF.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879696PMC
http://dx.doi.org/10.1186/s12933-021-01243-4DOI Listing

Publication Analysis

Top Keywords

adverse event
12
atrial fibrillation
8
food drug
8
drug administration
8
administration adverse
8
event reporting
8
reporting system
8
atc10 drugs
8
reporting
5
sglt-2 inhibitors atrial
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!